Vera Therapeutics, Inc. (NASDAQ:VERA) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Vera Therapeutics, Inc. (NASDAQ:VERA) has been given a consensus rating of “Moderate Buy” by the thirteen analysts that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and eleven have issued a buy recommendation on the company. The average 1 year target price among analysts that have covered the stock in the last year is $84.5833.

VERA has been the topic of a number of research analyst reports. HC Wainwright boosted their price objective on shares of Vera Therapeutics from $110.00 to $125.00 and gave the company a “buy” rating in a report on Wednesday, July 8th. Needham & Company LLC set a $125.00 price target on Vera Therapeutics in a research report on Wednesday, July 8th. William Blair reiterated an “outperform” rating on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. TD Cowen raised their price objective on Vera Therapeutics from $73.00 to $78.00 and gave the stock a “buy” rating in a research note on Wednesday, July 8th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $60.00 target price on shares of Vera Therapeutics in a report on Tuesday, June 2nd.

Insider Transactions at Vera Therapeutics

In other Vera Therapeutics news, CEO Marshall Fordyce sold 46,250 shares of the firm’s stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $42.30, for a total transaction of $1,956,375.00. Following the completion of the transaction, the chief executive officer directly owned 151,994 shares of the company’s stock, valued at approximately $6,429,346.20. This trade represents a 23.33% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 83,250 shares of company stock worth $3,337,770. Company insiders own 15.90% of the company’s stock.

Institutional Trading of Vera Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in Vera Therapeutics by 7.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,905 shares of the company’s stock valued at $753,000 after purchasing an additional 2,210 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Vera Therapeutics by 22.4% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 98,013 shares of the company’s stock valued at $2,354,000 after purchasing an additional 17,907 shares during the last quarter. Jane Street Group LLC grew its position in Vera Therapeutics by 297.1% during the 1st quarter. Jane Street Group LLC now owns 41,578 shares of the company’s stock worth $999,000 after purchasing an additional 62,678 shares during the period. JPMorgan Chase & Co. grew its position in Vera Therapeutics by 550.5% during the 2nd quarter. JPMorgan Chase & Co. now owns 310,547 shares of the company’s stock worth $7,316,000 after purchasing an additional 262,805 shares during the period. Finally, Legal & General Group Plc raised its stake in shares of Vera Therapeutics by 1.7% during the 2nd quarter. Legal & General Group Plc now owns 50,418 shares of the company’s stock valued at $1,188,000 after buying an additional 825 shares during the last quarter. Institutional investors and hedge funds own 99.21% of the company’s stock.

Vera Therapeutics Stock Down 2.5%

VERA stock opened at $35.45 on Friday. The firm has a 50 day moving average of $37.00 and a 200 day moving average of $40.14. The stock has a market capitalization of $2.54 billion, a PE ratio of -6.40 and a beta of 0.92. The company has a quick ratio of 13.64, a current ratio of 13.64 and a debt-to-equity ratio of 0.15. Vera Therapeutics has a 52 week low of $19.07 and a 52 week high of $56.05.

Vera Therapeutics (NASDAQ:VERA) last released its earnings results on Thursday, May 7th. The company reported ($1.69) earnings per share for the quarter, missing the consensus estimate of ($1.33) by ($0.36). During the same period in the prior year, the firm earned ($0.81) EPS. Sell-side analysts forecast that Vera Therapeutics will post -6.37 earnings per share for the current year.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.